2'-O-Ethyladenosin | 52842-98-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2'-O-Ethyladenosin
• 英文别名: O^2'-ethyl-adenosine；2'-O-ethyladenosine；(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-ethoxy-2-(hydroxymethyl)oxolan-3-ol
• CAS: 52842-98-5
• 化学式: C₁₂H₁₇N₅O₄
• 分子量: 295.298
• InChiKey: WPRAWTYWHYORKM-WOUKDFQISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  129
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• Adenosindeaminase inhibitor
  申请人：NIPPON ZOKI PHARMACEUTICAL CO., LTD.

  公开号：EP0601322A2

  公开（公告）日：1994-06-15

  The use of a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof wherein each of R₁, R₂ and R₃ which may be same or different is hydrogen or alkyl; and R and X have the meanings given in the specification, for the preparation of a medicament which is an adenosinedeaminase inhibitor is disclosed. Some of the compounds of formula (I) are novel compounds. They may be used for the making of a medicament which is for the prevention or therapy of ischemic heart diseases, diseases caused by cerebrovascular disorders, renal diseases and allergic diseases and of post-operative complicated diseases involved with activated oxygen which is generated in ischemic areas during the recirculation of blood after operations.

  使用以下通式（I）代表的化合物或其药学上可接受的盐 其中R₁、R₂和R₃可以相同或不同，各自为氢或烷基；R和X具有说明书中给出的含义。一些式（I）化合物是新型化合物。它们可用于制备预防或治疗缺血性心脏病、脑血管疾病、肾脏疾病和过敏性疾病以及术后复杂疾病的药物，这些疾病与术后血液再循环过程中在缺血区域产生的活性氧有关。
• Compositions and methods for detecting and modulating rna activity and gene expression
  申请人：ISIS PHARMACEUTICALS, INC.

  公开号：EP1418179A2

  公开（公告）日：2004-05-12

  Compositions and methods for modulating the activity of RNA and DNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. Reactive portions which act, alternatively, through phosphorodiester bond cleavage, through backbone sugar bond cleavage or through base modification are preferably employed. Groups which improve the pharmacodynamic and pharmacokinetic properties of the oligonucleotides are also useful in accordance with certain embodiments of this invention. Delivery of the reactive or non-reactive functionalities into the minor groove formed by the hybridization of the composition with the target RNA is also preferably accomplished. Therapeutics, diagnostics and research methods are also disclosed. Synthetic nucleosides and nucleoside fragments are also provided useful for elaboration of oligonucleotides and oligonucleotide analogs for such purposes.

  本文公开了调节 RNA 和 DNA 活性的组合物和方法。根据优选的实施方案，反义组合物由靶向部分和反应部分组成。反应部分最好通过磷酸二酯键裂解、骨架糖键裂解或碱基修饰起作用。根据本发明的某些实施方案，改善寡核苷酸药效学和药代动力学特性的基团也是有用的。最好还能将反应性或非反应性官能团输送到组合物与目标 RNA 杂交形成的次凹槽中。本发明还公开了治疗、诊断和研究方法。本发明还提供了合成核苷和核苷片段，可用于制备用于上述目的的寡核苷酸和寡核苷酸类似物。
• Novel adenosine derivatives and pharmaceutical compositions containing them as an active ingredient
  申请人：NIPPON ZOKI PHARMACEUTICAL CO. LTD.

  公开号：EP0269574B1

  公开（公告）日：1992-03-18
• US4843066A
  申请人：——

  公开号：US4843066A

  公开（公告）日：1989-06-27
• US5773603A
  申请人：——

  公开号：US5773603A

  公开（公告）日：1998-06-30